Figure 2From: Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 ≥ 50 cells/mm3Immunological outcomes between the 2 groups at 48 weeks of ART.Back to article page